EcoDrugPlus

Dopamine Receptor D4b

Ensembl ID : ENSSAUG00010016818
Gene Symbol: DRD4B
1 Cross references
180 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSSAUG00010006694
Gene Symbol: DRD5
1 Cross references
147 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSSAUG00010016794
Gene Symbol: LOC115591620
3 Cross references
212 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSSAUG00010018128
Gene Symbol: LOC115573060
3 Cross references
200 Possible Orthologues:

Echinoderm Microtubule-Associated Protein-Like 4

Ensembl ID : ENSSAUG00010016554
Gene Symbol: LOC115597163
2 Cross references
207 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSSAUG00010001887
Gene Symbol: ENPP2
1 Cross references
226 Possible Orthologues:

Egl Nine Homolog 1-Like

Ensembl ID : ENSSAUG00010014055
Gene Symbol: LOC115569167
2 Cross references
191 Possible Orthologues:

Egl Nine Homolog 3-Like

Ensembl ID : ENSSAUG00010013399
Gene Symbol: LOC115566499
3 Cross references
198 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSAUG00010011820
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Ell-Associated Factor Eaf-Like

Ensembl ID : ENSSAUG00010014548
Gene Symbol: LOC115591563
2 Cross references
190 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSSAUG00010016760
Gene Symbol: LOC115596873
3 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSSAUG00010020842
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).